The HCPLive spondyloarthritis page is a resource for medical news and expert insights on spondylitis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for autoimmune disease, and more.
October 23rd 2024
Malignancy-related IBP has distinct features: shorter diagnosis time, higher ESR/CRP/LDH, lower hemoglobin, and often involves metastasis or paraneoplastic causes.
Treatment of Plaque Psoriasis Taking Big Steps Forward Part 2
While several new treatment options for plaque psoriasis and psoriatic arthritis have launched in recent years, there is still much work to be done in the field to help patients through long stretches of care.
Stelara Recommended to Treat Psoriatic Arthritis in the United Kingdom
The National Institute for Health and Care Excellence in United Kingdom has recommended Janssen's Stelara for the treatment of psoriatic arthritis, adding to its recommendation of the drug already to treat plaque psoriasis.
Scientists Identify Mechanism of Action of Potential Psoriasis Therapy
March 12th 2015Researchers in Germany have figured out the process by which interleukin 4 (IL-4) inhibits inflammation, pointing the way toward a possible treatment for psoriasis, psoriatic arthritis, and other autoimmune diseases.
Researchers Identify Potential Protein Triggers of Psoriasis
February 20th 2015Researchers have reportedly identified several proteins that are highly prevalent in human psoriasis and may play an important role in the development and progression of the disease and its co-morbidities and complications, including psoriatic arthritis.
Secukinumab Effective for Treatment-Resistant Ankylosing Spondylitis
November 18th 2014A Phase 3 trial of the monoclonal antibody secukinumab indicates it is an effective treatment for patients with ankylosing spondylitis (AS) incompletely treated by standard therapy, according to data presented at the 2014 American College of Rheumatology meeting.
Patients with Psoriatic Arthritis Tend to Quickly Modify or Abandon Initial Treatment
October 2nd 2014The majority of patients with psoriatic arthritis treated with disease-modifying antirheumatic drugs will switch medications, discontinue treatment, or add an additional medicine, usually within a few months of initiating treatment.
Oral Medication Option May Lead to Improved Treatment Adherence in Patients with Psoriatic Arthritis
September 4th 2014Until apremilast was approved earlier this year, patients with psoriatic arthritis had to rely primarily on injectable therapies, which contributed to less than optimal treatment adherence in many patients.
Apremilast and the Future of Psoriatic Arthritis Treatment
August 21st 2014When it was approved by the FDA in March 2014, apremilast became the first oral medication approved for the treatment of psoriatic arthritis (PsA). Data from clinical trials showed it to be an effective option for patients, with a safer side effect profile than currently used PsA treatments.